Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

COMPARATIVE FINANCIALS (UNAUDITED)

COMPARATIVE FINANCIALS (UNAUDITED)

12 Months Ended

Dec. 31, 2022

NOTE 9 - COMPARATIVE FINANCIALS (UNAUDITED)

NOTE 9 – COMPARATIVE FINANCIALS (UNAUDITED)

The Company changed its fiscal year end from August 31 to December 31 effective December 31, 2021. The unaudited consolidated results of operations for the year ended December 31, 2021 is as follows:

	Year ended
	December 31,
	2021
	(unaudited)
OPERATING EXPENSES
General and administrative	$	5,633
Research and development		3,784
Total Operating Expenses		9,417

Loss from Operations		(9,417	)

OTHER INCOME
Interest income		2
Net change in market value		8
Change in fair value of derivative liabilities		-
Total other income		10

Provision for income taxes		-

NET LOSS	$	(9,407	)

OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized loss on available-for-sale securities		(5	)
Foreign currency translation adjustments		(54	)
Total Other Comprehensive Income (Loss)		(59	)

TOTAL COMPREHENSIVE LOSS	$	(9,466	)

Basic and Diluted Loss per Common Share	$	(5.24	)

Basic and Diluted Weighted Average Common Shares Outstanding		1,795